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Abstract. – OBJECTIVE: To evaluate whether 
Sudden Sensorineural Hearing Loss (S-SNHL) 
may be an early symptom of Multiple Sclerosis 
(MS).
MATERIALS AND METHODS: A systematic 
review was conducted using the following key-
words: “Multiple sclerosis, hearing loss, sudden 
hearing loss, vertigo, tinnitus, magnetic reso-
nance imaging, otoacoustic emission, auditory 
brainstem responses, white matter lesions, sen-
sorineural hearing loss, symptoms of MS and 
otolaryngology, nerve disease and MS”. Only 
the articles that included results of at least one 
auditory test and MRI were considered. We eval-
uated the prevalence of SNHL in patients with 
MS, the presence of different forms of SNHL 
(S-SNHL and Progressive SNHL (P-SNHL)) and 
their correlation with the stage of MS, the results 
of electrophysiological tests, and the location (if 
any) of MS lesions as detected by white matter 
hyperintensities in the MRI.
RESULTS: We reviewed a total of 47 articles, 
which included 29 case reports, 6 prospective 
studies, 6 cohort studies, 4 case-control studies, 
and 2 retrospective studies. 25% of patients suf-
fered from SNHL. S-SNHL typically occurred in 
the early stage of the disease (92% of patients) 
and was the only presenting symptom in 43% of 
female subjects. Instead, P-SNHL occurred in the 
late stage of MS (88% of patients). Auditory Brain-
stem Responses (ABR) were abnormal in all MS 
patients with S-SNHL. When S-SNHL appeared 
during the early stage of the disease, MS lesions 
were found in the brain in 60% of patients and in 
the Internal Auditory Canal in 40% of patients. 
ABR remained abnormal after recovery. 
CONCLUSIONS: S-SNHL can be an early man-
ifestation of MS and should always be consid-
ered in the differential diagnosis of this condi-
tion, especially in women. The pathophysiology 
can be explained by involvement of microglia at-
tacking the central and/or peripheral auditory 
pathways as indicated by WMHs. 
Key Words
Multiple sclerosis, Hearing loss, Sudden hearing 
loss, Auditory findings, Disease onset.
Introduction
Multiple sclerosis (MS) is one of the most com-
mon neurodegenerative diseases in the United 
States and Europe1-3. Sudden Sensorineural Hearing 
Loss (S-SNHL) is one of the symptoms of MS4-34. In 
MS patients SNHL can present in different forms; it 
can appear as S-SNHL early in the disease process 
or as P-SNHL in late stages of the disease as a result 
of a progressive involvement of the hearing path-
ways5,6,8,11. The origin of SNHL can be peripheral or 
central12-14; SNHL can be due to damage involving 
brain, nerve, or inner ear cells20. Although more 
common in early stages of the disease, S-SNHL 
can also occur in later stages, albeit rarely4-18. The 
often-reported temporary nature of hearing loss can 
be related to relapsing/remitting events that occur 
during the course of MS or to the use of corticoste-
roids21 which are able to fight the systemic inflam-
mation generated by MS22.
While the importance of hearing symptoms 
such as SNHL and tinnitus as early symptoms of 
MS has been highlighted by many studies, the sig-
nificance of S-SNHL20 as a presenting symptom of 
MS is largely underestimated. Arguably, this is due 
to its temporary nature and to the relatively high 
frequency of S-SNHL. There are more than 66,000 
new cases of S-SNHL in the United States every 
year23 and in 90% of cases S-SNHL is diagnosed 
as idiopathic and treated with corticosteroids. We 
speculate that a percentage of patients diagnosed 
with idiopathic S-SNHL may be affected by MS 
and a prompt treatment with steroids can contribute 
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to under-estimation and delayed diagnosis. The aim 
of this review is to evaluate whether S-SNHL in MS 
patients may be an early symptom of the disease. 
The awareness of MS-associated SNHL as a single 
presenting symptom of MS could decrease the risk 
of misdiagnosis and enable early intervention. To 
this end, we calculated the prevalence of SNHL in 
our sample of MS patients, we identified the pa-
tients with S-SNHL and P-SNHL, and we analyzed 
whether there is a difference in the hearing frequen-
cies (from 250 to 8000 Hz) involved in each form 
of SNHL. Finally, we looked for the presence of 
WMHs in patients’ MRIs of hearing pathways and 
assessed the correlation between WMHs presence 
and SNHL.
Materials and Methods
Two researchers independently searched PubMed, 
Scopus, and Google Scholar using the following 
keywords: “Multiple sclerosis (MS), hearing loss, 
sudden hearing loss, tinnitus, Magnetic Resonance 
Imaging (MRI), Pure Tone Audiometry (PTA), Oto-
acoustic Emission (OAE), Auditory Brainstem Re-
sponses (ABR), white matter lesions, White Matter 
Hyperintensities (WMH), sensorineural hearing loss 
(SNHL), symptoms of MS and otolaryngology, nerve 
disease and MS”. Both researchers independently 
selected and reviewed the abstracts that included the 
term “multiple sclerosis” and at least one of the key-
words listed above. The selected articles were then 
thoroughly read. All publication types from 1960 to 
December 2017, in English, French, or Italian were 
considered for analysis, including case reports, case 
series, epidemiological studies, case-control studies, 
as well as prospective and retrospective studies. Ar-
ticles were evaluated by a native speaker. In order to 
be included the articles had to contain results of at 
least one auditory test (Pure Tone Audiometry, OAE, 
and/or ABR).
For the patients with SNHL we recorded gen-
der, age, stage of MS, frequency range lost due 
to the hearing loss (Table I), results of ABR (la-
tency and amplitude shape, presence/absence of 
response) and OAE (presence/absence) tests, pres-
ence and location (brain or IAC/cochlea) of WMHs 
in T2-MRI sequences, and symptoms resolution. 
SNHL was classified as S-SNHL or P-SNHL. The 
MS stage was recorded as reported in each study, 
namely “early” when patients were first diagnosed 
with the disease, and “late” when patients had been 
diagnosed with MS several years (> 2 years) prior 
to enrollment into the study.
Statistical Analysis
The analysis aimed at investigating whether 
there was a time difference between S-SNHL and 
P-SNHL presentation in the disease process. Chi-
Square (c2) was used to evaluate the time differ-
ence in the presentation of S-SNHL and P-SNHL 
in the early or late stage of the disease. One-way 
ANOVA and Holm-Bonferroni were used to eval-
uate the difference in the hearing frequencies for 
S-SNHL and PSNHL. Spearman test was used 
to identify the correlation between the location 
of the lesions in the MRI and the type of SNHL. 
c2-test was used to evaluate whether a gender 
difference existed in association with onset and 
type of SNHL. For all tests, p-values <0.05 were 
considered statistically significant. 
Results
Review of Literature 
We reviewed 177 publications. Among them, 
47 articles matched our criteria for inclusion in 
the review4-6,8-18,24,24-57 and included 29 case re-
ports, 6 prospective studies, 6 cohort studies, 4 
case-control studies, and 2 retrospective studies 
(Table I). Data from a total of 1533 patients were 
collected and analyzed (Figure 1); data from 39 
patients were published in the form of case re-
ports (0.02% of patients). 72% of patients were 
women, 28% were men, and average patient age 
was 35.7 years old (SD: 9.5; C.I. 95%: 13-82). 83% 
of patients were affected by relapsing-remitting 
MS and the remaining 17% by the progressive 
form. 69% of patients were affected by S-SNHL 
and the 31% from P-SNHL. 92% of S-SNHL 
episodes appeared in the early stage of MS, while 
P-SNHL occurred in late stages in 88% of cases. 
S-SNHL vs. P-SNHL, Distribution 
in the Different Stages of MS, 
and Involved Frequencies
Of the 1533 patients included in this anal-
ysis, 25% were affected by a form of SNHL 
(Table I) as demonstrated by the results of their 
audiometric test; the remainder presented nor-
mal hearing functions. S-SNHL was present in 
69% of cases (78% of cases were bilateral and 
22% were unilateral) with variable severity, from 
complete deafness to middle-to-severe hearing 
impairment. P-SNHL (91% bilateral, 9% unilater-
al) was observed in 31% of cases with a severity 
range from mild hearing impairment to complete 
hearing loss. 
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S-SNHL and P-SNHL were differently dis-
tributed in the different stages of MS (Figure 
2). S-SNHL was more frequent in the early 
stage of MS (92%) (c2: p<0.0001) (Odds Ratio: 
316; CI 95%: 81.1-1232), while P-SNHL preva-
lently occurred in the late stage of the disease 
(88%) (c2: p<0.0001) (Odds Ratio: 316 CI 95%: 
82-1132).
Figure 1. The plot shows the method used 
to identify the articles that were included in 
this review.
Figure 2. A, Distribution of S-SNHL and P-SNHL in the early and later stages of MS. B, Hearing loss frequencies distribution 
in the early stage (up) and later stage (down) of the disease.
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S-SNHL and P-SNHL affected different fre-
quencies as shown in Figure 2. S-SNHL equally 
affected frequencies from 250 to 8000 Hz with-
out statistically significant differences (One-way 
ANOVA p=0.3). P-SNHL mainly affected high 
frequencies (2000 to 8000 Hz) (p<0.0001 for 
2000, 4000 and 8000 Hz). 43% of women devel-
oped S-SNHL in the early stage of MS. In women, 
S-SNHL was more common than in men (73% 
and 27%, respectively; p<0.0001) and presented 
more frequently than P-SNHL both in early and 
late stages of MS (81% and 19% respectively). In 
men, there was no significant difference between 
the prevalence of S-SNHL and P-SNHL (49% vs. 
51%), and both forms of hearing loss equally oc-
curred in early and late stages of the disease (c2: 
p=0.12). OAEs were altered in 34% of MS patients 
(52). ABR waves were altered in terms of latency 
and/or amplitude in all MS patients, even in pres-
ence of a hearing threshold near the instrument 
detection limit (20 dB), as shown in Figure 3. The 
most common ABR abnormality was a non-spe-
cific abnormal wave shape (45%) with abnormal 
latency and/or amplitude. Residual abnormal ABR 
waves following S-SNHL recovery were observed 
in 18% of patients.
WMH Distribution in Brain and Ear 
Seventy percent (70%) of patients with S-SNHL 
in the early stage of MS displayed WMHs in 
their MRIs in brain and medulla (upper auditory 
pathways). 75% of patients with P-SNHL in the 
late stage of MS displayed WMHs in the Roof 
Entry Zone (REZ), cochlear nerve and cochlea 
(Figure 4). In patients who manifested S-SNHL 
as early symptom, the presence of WMHs in the 
upper hearing pathways was statistically signif-
icant (Spearman: p=0.006). Additionally, there 
was a statistically significant correlation between 
the lower hearing pathways involvement and the 
presence of P-SNHL (Spearman: p=0.004).
Discussion 
Our review included 1533 patients with MS, 
25% of whom reported either S-SNHL (17%)4,5,11-
18,22,24 or P-SNHL (8%)6,8-10. S-SNHL was more 
common than P-SNHL (70% of patients).
S-SNHL and P-SNHL presented in different 
stages of MS with different manifestations, with 
the former being more common in the early stage 
of MS (92%) and involving all frequencies (sim-
ilarly to the common form of Sudden Idiopathic 
SNHL), and the latter being more prevalent in the 
late stage of MS (88%) and involving mainly high 
frequencies. 
S-SNHL was the only initial symptom in the 
early stage of MS in 43% of women, consistently 
with the results observed from other authors18,47. 
In women, S-SNHL was more common than 
P-SNHL. In men, S-SNHL and P-SNHL present-
ed with equal frequency. 
The presence of S-SNHL in the early stage 
of MS in women was statistically significant 
compared to men (p<0.05). In men, S-SNHL 
and P-SNHL equally manifested (no statistically 
significant difference) in all stages of the disease. 
S-SNHL in women was also more common (81%) 
Figure 3.  The figure shows the different findings related to 
ABR observed in our sample.
Figure 4. The plot shows the distribution of the WMHs in 
the presence of S-SNHL P-SNHL. 
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than P-SNHL, which strongly supports the idea 
that S-SNHL should be considered as an early 
symptom of MS in young women, especially if 
they don’t have a history of hearing disorders. 
P-SNHL occurred more often in later stages of 
MS (88%) in both genders. The altered audiomet-
ric threshold, which involves frequencies between 
2000 and 8000 Hz, can mimic presbycusis and it 
could be misdiagnosed as early presbycusis rather 
than a symptom of MS when it appears in young 
subjects. The average age of the patients we ana-
lyzed was less than 40 years old, which supports the 
idea that MS-related P-SNHL may be easily missed.
ABR allows the investigation of different ar-
eas of the hearing pathways (Figure 5); its sen-
sitivity and high specificity in the detection of 
demyelination43-45,59-59 is extremely valuable in 
studying auditory disorders in MS patients, as 
widely supported by many studies35,43,45,56-58. ABR 
amplitude and latency were altered in all MS pa-
tients with SNHL. The abnormal latency and am-
plitude reflect the location of the damage in the 
auditory pathways, as detailed in the table in the 
left panel of Figure 5. Wave I was detectable only 
in 10% of cases, indicating a very high chance of 
cochlear nerve injury during MS attacks. The la-
tency of all waves was increased in 20% of cases 
indicating a reduction in the velocity of impulse 
transmission in auditory pathways. Waves were 
completely absent in 25% of the cases; although 
damage can occur in one or more areas of the 
auditory pathways, an early cochlear nerve in-
volvement is plausible. Finally, we identified a 
45% of “unspecific alterations” of ABR, namely 
generic wave alterations for which authors did not 
provide details. 
OAEs investigate the function of outer hair 
cells in the cochlea, and detect cochlear dam-
age that is not otherwise detectable using ABR. 
Thirty-four percent (34%) of MS patients dis-
played abnormal OAE, which suggests cochlear 
involvement in the context of MS. The relevance 
of the investigation of outer hair cell function in 
MS has been recently discussed by Di Stadio and 
Ralli59,60. We speculate that the altered OAE we 
observed in our sample may reflect a damage of 
outer hair cells61. In MS hair cells can be directly 
attacked by macrophages and suffer irreversible 
damage as a result of oxidative stress59; involve-
ment of hair cells can lead to abnormal OAE.
Figure 5. Upper side corner: the table summarizes the hearing pathways where each wave originates. Center: hearing pathways 
from periphery (cochlea) to the acoustic brain area are shown. Top right: the images show the amplitude and latency of a normal 
ABR.
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McKenna et al62 found microglia and mac-
rophages in cochlear structures that have been 
damaged by autoimmune diseases, including spi-
ral ligament, scala tympani, vestibuli surrounding 
spiral ganglions, modiolus, and the 8th cranial 
nerves. Microglia has been also found in WMHs 
of MS patients63,64. In our study, we found that 
WMHs were mostly present in the brain/medulla 
areas (70%) in the early stages of MS, which sup-
ports the idea that MS lesions in the upper auditory 
pathways can cause S-SNHL6,38. WMHs in IAC 
were more common in later stages of MS, which 
supports the idea that the nerves of IAC can be 
affected by the same demyelization process that 
affects other structures in MS42. In this study, we 
found WMHs in different parts of the auditory 
pathways (cortical area, medulla, cochlear nerve, 
and cochlea). WMHs are associated with activat-
ed, pathogenic microglia; the presence of WMSs 
in different anatomical areas can be explained by 
the microglia’s ability to move, which is typical 
of macrophages60. Both S-SNHL and P-SNHL 
may be associated with the pathogenic form of 
activated microglia. We could define two origins 
for these forms: a peripheral SNHL when cochlear 
nerve or cochlea is affected (as in P-SNHL) and a 
central SNHL when the upper auditory pathways 
are involved (as in S-SNHL). 
The temporary nature of S-SNHL can be ex-
plained by the microglia ability to change their 
phenotype from an aggressive (M1) to a neuro-
protective (M2) form65-67. Microglia can be pres-
ent in a “non-active” or “active” form, although 
the active form is usually differentiated in M1 
or M2 phenotypes (respectively pathogenic and 
neuroprotective). The M1 form is particularly 
aggressive and can induce damage by destroy-
ing upper auditory pathways64-70 or by directly 
attacking the peripheral auditory structures such 
as the cochlear nerve and the cochlea60 (Figure 
6). Microglia can also induce a progressive 
degeneration of the nerve sheath that mimics 
presbycusis as in P-SNHL; the slow progression 
of the degeneration may become symptomatic 
as reduced adaptation to noise 70,71, or as recruit-
ment phenomenon71; all these symptoms have 
been described in MS patients69-71. It is also 
possible that a massive microglia attack induces 
an enormous inflammation in the auditory path-
ways (central and/or peripheral) thereby causing 
a S-SNHL event71. 
As discussed above, microglia can change their 
form (active vs. non-active) and phenotype (M1 
vs. M2), and this ability to change state has been 
associated with the relapsing and remitting phases 
of MS72; the same mechanism may explain the 
spontaneous regression of S-SNHL in patients 
with MS when benign M2 form is prominent14,39. 
The change of microglia state can also be induced 
by drugs such as corticosteroids73. Corticosteroids 
that are the gold standard in the treatment of 
S-SNHL, may also contribute to under-diagnosis 
of MS-related S-SNHL, in fact their anti-inflam-
matory and immunosuppressive action is systemic 
by acting also on the inflammatory phenomena 
that arise from MS.
In the advanced phases of MS, the ability of 
microglia to change phenotype and state is reduced 
due to the increase of the oxidative stress72-73. M1 
is the prevalent form of microglia and induce pro-
gressive neuro-degeneration, which can involve 
the cochlear nerve and lead to P-SNHL. 
Figure 7 summarizes the differential di-
agnosis of SNHL in MS patients. Microglia 
can play a predominant role in damaging any 
area of the auditory pathways, as shown by 
the presence of WMHs in these locations62 and 
supported by the alteration observed in ABR 
(100% of subjects).
The nature and timing of S-SNHL and P-SN-
HL manifestation depends on the MS stage. 
S-SNHL seems to be more common at MS onset, 
especially in women. In this case, hearing loss is 
likely correlated to lesions in the auditory path-
ways, including brain (temporal area and auditory 
cortex) and medulla; IAC seems to be involved 
less frequently.
Figure 6. The ear modioulus of a mouse where it is possible 
to observe microglia. The red and yellow arrow indicates the 
staying and active form of microglia, respectively.
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Generally, 90% of patients who suffer from 
S-SNHL have been previously treated in a hospital 
setting and dismissed as “idiopathic” S-SNHL23. 
We identified a 17% of S-SNHL in patients with 
MS. We believe that this percentage is included in 
the 90% of idiopathic S-SNHL cases and that this 
data could increase the detection of misdiagnosed 
MS-related S-SNHL. In the relapsing-remitting 
MS, corticosteroids are commonly used as first-
line treatment; these drugs reduce inflammation 
and promote SNHL recovery, but at the same time, 
can mask the actual origin of the symptom74. 
Our work presents some limitations. There are 
several case reports included in the study; this 
may have biased the percentage of MS patients 
with SNHL. Another limitation is the insufficient 
number of case-control studies and cohort studies 
available in the literature, which precluded us from 
conducting a meta-analysis to correctly estimate 
the incidence and prevalence of SNHL in MS 
patients. Only a few studies analyzed hearing pa-
rameters in patients with SNHL, and some of these 
studies had to be excluded from our systematic 
review due to lack of data or important limitation 
in the study design72.
Conclusions
S-SNHL and P-SNHL present with different 
timing and frequency features, depending on the 
MS stage. S-SNHL seems to be more common in 
the early stage of MS especially in women, but 
this is probably related to the greater prevalence 
of the disease in this gender. Hearing loss is likely 
to be correlated with lesions in the auditory path-
ways, including brain and medulla; the involve-
ment of the IAC structure during the inflamma-
tory attack is less common. ABR was abnormal 
in 100% of MS patients; this test detects damage 
in the auditory pathways even when patients do 
not perceive it due to the involvement of high 
frequencies only. In conclusion, SNHL should be 
always considered in the differential diagnosis 
of MS, especially given its increased occurrence 
of S-SNHL in youth75. Otolaryngologists should 
always consider S-SNHL as either an only and/
or first symptom of MS, particularly in young 
women without a history of hearing impairment. 
Moreover, diagnostic protocols should include 
ABR and MRI, in addition to a detailed history 
and neurological examination.
Figure 7. The figure summarizes how M1 microglia aggression may involve the different structures of the hearing pathways 
(brain, cochlear nerve and cochlea). Microglia have two forms, resting and active: the active form has two phenotypes, the M1 
form that induces pathogenesis and the M2 form that is responsible for neurodegeneration.
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